Venous Thromboembolism with JAK Inhibitors and Other Immune-Modulatory Drugs: a Swedish Comparative Safety Study Among Patients with Rheumatoid Arthritis

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-223050

Nationwide register-based study in Sweden finds that patients with RA treated with JAKinibs in routine clinical practice are at increased risk of venous thromboembolism (VTE), compared with those treated with bDMARDs, an increase numerically confined to pulmonary embolism.

Following recent data, and the FDA and EMA warnings, regarding VTE risk with JAKinibs, Molander, et al. aimed to assess and compare the incidence of VTE, by type, in patients with RA treated with JAKinibs or bDMARDs, in clinical practice.